Skip to main content

Investors

Investors

Home › Home › Press Releases

Press Releases
Press Release RSS Feed (opens in new window)
Press release year list 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
August 13, 2019
Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment
August 13, 2019
Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
August 8, 2019
Ironwood Pharmaceuticals Announces Pricing of Upsized $350 Million Convertible Senior Notes Offering
August 6, 2019
Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes
July 30, 2019
Ironwood Pharmaceuticals Reports Second Quarter 2019 Results
July 18, 2019
Ironwood Pharmaceuticals to Host Second Quarter 2019 Investor Update Call
June 18, 2019
Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
June 13, 2019
Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston
June 3, 2019
Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D
May 9, 2019
Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019
May 7, 2019
Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference
May 2, 2019
Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance
April 18, 2019
Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call
April 16, 2019
Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020
April 1, 2019
Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company
March 14, 2019
Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement
March 7, 2019
Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference
March 4, 2019
Ironwood Pharmaceuticals to Present at Cowen Health Care Conference
February 26, 2019
Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering
February 21, 2019
Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
February 13, 2019
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update
January 28, 2019
Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call
January 28, 2019
Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation
January 15, 2019
Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C
Download PDF format download (opens in new window)
January 6, 2019
Ironwood Pharmaceuticals Appoints Michael Shetzline, M.D., Ph.D. as Chief Medical Officer
Download PDF format download (opens in new window)
January 4, 2019
Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation
Download PDF format download (opens in new window)
January 2, 2019
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Download PDF format download (opens in new window)
January 2, 2019
Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation
Download PDF format download (opens in new window)